Month: September 2018


Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Shots: The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, medical affairs, manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months Imetelstat is currently evaluated in […]Read More


Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine

Shots: Novartis to get royalty-free worldwide, intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing process, and Novartis will undertake distribution, regulatory and commercialization in China Novartis to pay $40M in the form of equity purchase for its 1,458,257 shares […]Read More


Lyra Therapeutics (Formally 480 Biomedicals) Developing Innovative Therapeutics for ENT

Shots: This round is led by Perceptive Advisors, RA Capital Management, ArrowMark Partners & Soleus Capital, along with existing investors Polaris Venture Partners, North Bridge Venture Partners & Intersouth Partners Funding will be utilized to plan P-II for LYR-210 in Chronic rhinosinusitis (CRS) Lyra is using its proprietary transmucosal platform for developing treatment for various […]Read More


I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more

Shots: I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products WuXiBody bispecifics have achieved 16g/L in cell culture titer, […]Read More


Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor

Shots: Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further develop and commercialize the develop product Anaeropharma has developed APS001F, a recombinant Bifidobacterium expresses Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, […]Read More